-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $98

Benzinga·07/29/2026 17:45:04
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $64 to $98.